Further studies are needed to confirm this mechanism in breast cancer as well as to examine the additive effects of ADAM10 inhibitors in combination with monoclonal anti-HER2 therapies, but the cleavage product HER2-ECD shows promise as a prognostic biomarker. This evidence concerns the gene ERBB2 and breast cancer.